Lymphoma, Mantle-Cell

"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).

Descriptor ID	D020522
MeSH Number(s)	C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525
Concept/Terms	Lymphoma, Mantle-Cell Lymphoma, Mantle-Cell Lymphoma, Mantle Cell Lymphomas, Mantle-Cell Mantle-Cell Lymphomas Lymphocytic Lymphoma, Diffuse, Poorly Differentiated Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated Mantle-Zone Lymphoma Lymphoma, Mantle-Zone Lymphomas, Mantle-Zone Mantle Zone Lymphoma Mantle-Zone Lymphomas Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated Lymphoma, Small-Cell, Centrocytic Mantle-Cell Lymphoma Mantle Cell Lymphoma Diffuse Lymphocytic Lymphoma, Poorly-Differentiated Diffuse Lymphocytic Lymphoma, Poorly Differentiated Lymphoma, Centrocytic Small-Cell Centrocytic Small-Cell Lymphoma Centrocytic Small-Cell Lymphomas Lymphoma, Centrocytic Small Cell Lymphomas, Centrocytic Small-Cell Small-Cell Lymphoma, Centrocytic Small-Cell Lymphomas, Centrocytic Lymphoma, Lymphocytic, Intermediate Lymphoma, Lymphocytic, Intermediate

Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Lymphoma [C04.557.386]
Lymphoma, Non-Hodgkin [C04.557.386.480]
Lymphoma, Mantle-Cell [C04.557.386.480.525]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Lymphoma [C15.604.515.569]
Lymphoma, Non-Hodgkin [C15.604.515.569.480]
Lymphoma, Mantle-Cell [C15.604.515.569.480.525]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Lymphoma [C20.683.515.761]
Lymphoma, Non-Hodgkin [C20.683.515.761.480]
Lymphoma, Mantle-Cell [C20.683.515.761.480.525]

Below are MeSH descriptors whose meaning is related to "Lymphoma, Mantle-Cell".

Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in this website by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications.

Bar chart showing 33 publications over 16 distinct years, with a maximum of 5 publications in 2009

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	2	0	2
2003	2	0	2
2005	2	0	2
2006	1	0	1
2007	0	1	1
2009	4	1	5
2010	3	1	4
2012	2	0	2
2014	1	1	2
2015	3	0	3
2016	1	0	1
2017	1	0	1
2018	2	0	2
2019	1	0	1
2022	1	0	1
2023	3	0	3

Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles.

Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SM, Stephens DM, Bachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzm?n A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, Bi C. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium. J Hematol Oncol. 2023 12 16; 16(1):122.

View in: PubMed
Karmali R, Abramson JS, Stephens DM, Barnes J, Winter JN, Ma S, Gao J, Kaplan J, Petrich AM, Hochberg E, Takvorian T, Mi X, Nelson V, Gordon LI, Pro B. Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Adv. 2023 12 12; 7(23):7361-7368.

View in: PubMed
Hofacker SA, Schmidt EP. Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia. Reply. N Engl J Med. 2023 07 06; 389(1):95.

View in: PubMed
Shah NN, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper TC, Hussaini M, Tao J, Chavez JC, Isenalumhe L, Gaballa S, Saeed H, Bello C, Sokol L, Pinilla-Ibarz J, Shah BD. Frontline treatment approaches in TP53-aberrant mantle cell lymphoma. Leuk Lymphoma. 2023 01; 64(1):230-233.

View in: PubMed
Kramer S, Uppal G, Wang ZX, Gong JZ. Mantle Cell Lymphoma With Hodgkin and Reed-Sternberg Cells: Review With Illustrative Case. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):8-14.

View in: PubMed
Hayakawa K, Formica AM, Nakao Y, Ichikawa D, Shinton SA, Brill-Dashoff J, Smith MR, Morse HC, Hardy RR. Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice. J Immunol. 2018 07 15; 201(2):804-813.

View in: PubMed
Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Fanale M, Orlowski R, Kwak LW, Neelapu S, Oki Y, Pro B, Younes A, Samaniego F, Fowler N, Hartig K, Valentinetti M, Smith J, Ford P, Naig A, Medeiros LJ, Kantarjian HM, Goy A. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018 06 15; 124(12):2561-2569.

View in: PubMed
Shields CL, Lally SE, Shields JA. Mantle-Cell Lymphoma-Taming the Tiger. JAMA Ophthalmol. 2017 12 01; 135(12):1374-1375.

View in: PubMed
Gru AA, Hurley MY, Salavaggione AL, Brodell L, Sheinbein D, Anadkat M, Porcu P, Frater JL. Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases. J Cutan Pathol. 2016 Dec; 43(12):1112-1120.

View in: PubMed
Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan; 172(1):80-8.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement